PROTEOME SCIENCES PLC

Board/Management Information • Jun 1, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7786Z

Proteome Sciences PLC

01 June 2016

PRESS RELEASE

Proteome Sciences plc

(the "Company" or the "Group")

CEO Appointment

1st June 2016

Proteome Sciences is pleased to announce the appointment of  Jeremy Haigh as a director and CEO of the Company on 1st June 2016 as indicated in the press release to shareholders dated  18th May 2016. He is a strong advocate of Precision Medicine and will bring numerous industry contacts and considerable commercial experience to the role.

Jeremy is an established leader in the biopharmaceutical sector with 30 years in clinical and operational research and development, principally at Merck and Amgen where most recently he was European Chief Operating Officer, R&D.

His basic training was in neuropharmacology and he has been significantly involved in healthcare policy and government affairs in the UK and Europe having served on the board of the BioIndustry Association (BIA), the European Federation of Pharmaceutical Industries (EFPIA) Research Directors Group, and the Association of the British Pharmaceutical Industry Innovation Board (ABPI). He is currently the Chairman of Cogent Skills Limited and a member of Imperial College Health Partners Advisory Council.The following information regarding the appointment of Jeremy Rupert Michael Haigh, aged 55 , is disclosed under Schedule 2(g) of the AIM Rules for Companies:

Current directorships and/or partnerships:	Former directorships and/or     partnerships (within the last 5 years):
Cogent SSC Ltd	Amgen Ltd BioIndustry Association Biovex Ltd Amgen Research (Munich) GmbH Onyx Pharmaceuticals (UK) Ltd

Mr. Haigh does not currently hold any ordinary shares in the Company. There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies

With the news of his appointment, Jeremy Haigh commented,

"I am delighted to be joining Proteome Sciences at a time of tremendous opportunity. The challenge of developing more precise therapeutics coupled with growing patient expectations is creating a highly receptive environment for our enabling technologies and I look forward to working with the board and the entire team to realise this potential."

Christopher Pearce added,

"As Chairman, I look forward to working closely with Jeremy and the executive team to help them exploit the considerable commercial opportunities arising in Precision Medicine from the outstanding proteomics platform Proteome Sciences has established to deliver truly personalised medicine."

ENDS

For further information please contact:

Proteome Sciences plc
Christopher Pearce, Executive Chairman
Dr. Ian Pike, Chief Operating Officer	Tel: +44 (0)1932 865065
Geoff Ellis, Finance Director
finnCap Limited (nominated adviser & broker) Geoff Nash/James Thompson	Tel : +44 (0)20 7220 0500
Public Relations
IKON Associates	Email: adrian@ikonassociates.com
Adrian Shaw	Tel: +44 (0)1483 271291
	Mobile +44(0)7979 900733

Notes for editors:

About Proteome Sciences plc (www.proteomics.com)

With its HQ in Cobham, UK and laboratory facilities in London and Frankfurt, Proteome Sciences is a global leader in applied proteomics offering high sensitivity, proprietary technologies and workflows in cell signalling pathways (SysQuant®, TMTcalibrator™) and in protein biomarker discovery, validation and assay development.

PS Biomarker Services® provides proteomics outsourcing services and proprietary biomarker assays from its ISO 9001: 2008 facility in Frankfurt, Germany to pharmaceutical, biotechnology, diagnostics companies and academia.

Proteome Sciences' research has discovered a large number of novel protein biomarkers in key human diseases with a focus mainly in neurological/neurodegenerative conditions and in cancer. It has patented blood biomarkers in Alzheimer's disease, stroke, brain damage and cancers for diagnostic and treatment applications that are available for licenses.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAZFLFXQEFXBBE